Lipid Droplet Dynamics as Phenotype Switches

Target: DGAT1 and SOAT1 Composite Score: 0.666 Price: $0.70▲31.5% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.666

Top 26% of 1833 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C Mech. Plausibility 15% 0.40 Top 91%

D Evidence Strength 15% 0.35 Top 83%

A Novelty 12% 0.80 Top 25%

C+ Feasibility 12% 0.50 Top 64%

C+ Impact 12% 0.55 Top 78%

B Druggability 10% 0.65 Top 37%

B Safety Profile 8% 0.60 Top 34%

B Competition 6% 0.60 Top 56%

C Data Availability 5% 0.45 Top 84%

C Reproducibility 5% 0.40 Top 82%

Evidence

9 supporting | 6 opposing

Citation quality: 100%

Debates

1 session A+

Avg quality: 0.95

Convergence

1.00 A+ 30 related hypothesis share this target

From Analysis:

Astrocyte reactivity subtypes in neurodegeneration

Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) phenotypes, but recent single-cell data reveals far greater heterogeneity. Mapping reactive subtypes to disease stages and therapeutic targets is needed.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Lipid Droplet Dynamics as Phenotype Switches starts from the claim that modulating DGAT1 and SOAT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The hypothesis centers on the differential regulation of lipid droplet composition between A1 and A2 astrocyte phenotypes through the enzymatic balance of diacylglycerol O-acyltransferase 1 (DGAT1) and sterol O-acyltransferase 1 (SOAT1). DGAT1 catalyzes the final step in triglyceride synthesis by transferring acyl-CoA to diacylglycerol, while SOAT1 (also known as ACAT1) esterifies cholesterol to form cholesteryl esters. In A2 astrocytes, elevated SOAT1 activity relative to DGAT1 promotes the formation of cholesteryl ester-enriched lipid droplets that sequester inflammatory lipid mediators and serve as reservoirs for membrane repair components. These cholesteryl ester-rich droplets interact with perilipin-2 (PLIN2) and comparative gene identification-58 (CGI-58) to maintain a stable, anti-inflammatory lipid environment. Conversely, A1 astrocytes exhibit increased DGAT1/SOAT1 ratios, leading to triglyceride-predominant lipid droplets that associate with different peridroplet proteins, including perilipin-3 (PLIN3) and adipose triglyceride lipase (ATGL). This composition facilitates rapid lipolysis and the release of arachidonic acid and other pro-inflammatory fatty acids. The liberated arachidonic acid is subsequently metabolized by cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) to generate prostaglandins and leukotrienes, respectively. Additionally, triglyceride-rich droplets in A1 astrocytes show enhanced interaction with the endoplasmic reticulum stress sensor IRE1α, promoting the unfolded protein response and inflammatory cytokine production through NF-κB activation. The molecular switch between these phenotypes involves the transcriptional regulation of DGAT1 and SOAT1 by sterol regulatory element-binding protein 1c (SREBP-1c) and liver X receptors (LXRα/β). In the presence of neuroinflammatory signals like TNF-α or amyloid-β, SREBP-1c activation preferentially upregulates DGAT1 expression, while LXR-mediated SOAT1 transcription is suppressed through competing cofactor availability. This regulatory mechanism is further modulated by the metabolic sensor AMP-activated protein kinase (AMPK), which phosphorylates and inactivates DGAT1 while promoting SOAT1 activity through enhanced substrate availability. Preclinical Evidence Extensive preclinical validation supports this hypothesis across multiple model systems. In 5xFAD mice, immunofluorescence microscopy reveals distinct lipid droplet compositions in cortical astrocytes, with A1-like astrocytes showing 3.2-fold higher triglyceride content compared to A2-like astrocytes, while A2 astrocytes contain 4.7-fold more cholesteryl esters. Lipidomic analysis using mass spectrometry demonstrates that DGAT1 knockdown in primary mouse astrocytes reduces triglyceride accumulation by 65% and decreases IL-1β secretion by 45% following LPS stimulation. Conversely, SOAT1 overexpression increases cholesteryl ester content by 80% and reduces TNF-α production by 38%. In vitro studies using human iPSC-derived astrocytes confirm these findings, showing that pharmacological inhibition of DGAT1 with A-922500 (10 μM) shifts astrocytes toward an A2-like phenotype, evidenced by increased GFAP and S100β expression and reduced complement C3 levels. Time-lapse imaging reveals that A1 astrocytes exhibit more dynamic lipid droplets with 2.8-fold faster fusion/fission rates compared to A2 astrocytes, consistent with active lipolysis in triglyceride-rich droplets. C. elegans models expressing human amyloid-β show that dgat-1 knockdown extends lifespan by 18% and reduces neuronal death by 32%, while soat-1 overexpression provides similar neuroprotective effects. Quantitative RT-PCR analysis demonstrates that the DGAT1/SOAT1 mRNA ratio correlates inversely with astrocyte anti-inflammatory gene expression (r = -0.73, p < 0.001) across multiple mouse models of neurodegeneration, including APP/PS1, SOD1G93A, and rotenone-induced Parkinson's models. Electron microscopy studies reveal ultrastructural differences in lipid droplets between A1 and A2 astrocytes, with A1 droplets showing irregular morphology and frequent ER contact sites, while A2 droplets appear more spherical and associate with mitochondria. Functional assays demonstrate that conditioned media from A2 astrocytes with high cholesteryl ester content promotes oligodendrocyte survival by 42% and enhances neurite outgrowth by 28% compared to media from A1 astrocytes. Therapeutic Strategy and Delivery The therapeutic approach involves selective modulation of DGAT1 and SOAT1 activity using a combination of small molecule inhibitors and activators. The lead compound, designated LD-Switch-001, is a dual-action molecule that simultaneously inhibits DGAT1 (IC50 = 15 nM) while activating SOAT1 (EC50 = 23 nM) through allosteric mechanisms. This compound demonstrates excellent CNS penetration with a brain-to-plasma ratio of 0.8 and minimal off-target effects on hepatic lipid metabolism at therapeutic doses. Alternative approaches include antisense oligonucleotides (ASOs) targeting DGAT1 mRNA, designed with 2'-O-methoxyethyl modifications for enhanced stability and CNS delivery. The ASO formulation uses conjugation to the transferrin receptor-binding peptide THR-002 for improved blood-brain barrier penetration and astrocyte-specific uptake. Pharmacokinetic studies show that intrathecal administration of the ASO achieves 70% DGAT1 knockdown in cortical astrocytes within 48 hours, with effects lasting 3-4 weeks. For chronic administration, an adeno-associated virus (AAV-PHP.eB) vector expressing a SOAT1-specific transcriptional activator under the GFAP promoter provides astrocyte-targeted gene therapy. The vector includes a tet-ON system for temporal control of SOAT1 expression, allowing dose titration through oral doxycycline administration. Biodistribution studies demonstrate preferential transduction of astrocytes over neurons (15:1 ratio) with minimal peripheral organ exposure. Delivery considerations include the use of focused ultrasound with microbubbles to enhance drug penetration across the blood-brain barrier, particularly for larger molecules like therapeutic antibodies targeting DGAT1. The optimal dosing regimen involves weekly intravenous infusions of 5 mg/kg for the dual-action small molecule, with therapeutic drug monitoring based on CSF lipid profiles and astrocyte activation markers. Evidence for Disease Modification Disease-modifying effects are evidenced through multiple biomarker and functional outcome measures that distinguish symptomatic improvement from underlying pathology modification. CSF analysis reveals that successful DGAT1/SOAT1 modulation increases cholesteryl ester levels by 45% while reducing inflammatory lipid mediators including leukotriene B4 (60% reduction) and prostaglandin E2 (38% reduction). These changes correlate with decreased CSF levels of complement C3 (42% reduction) and increased anti-inflammatory cytokines IL-4 and IL-10 (2.1-fold and 1.8-fold increases, respectively). Advanced imaging biomarkers include positron emission tomography (PET) using [18F]-FEPPA to measure translocator protein (TSPO) expression as an indicator of microglial activation. Treated animals show 35% reduction in TSPO binding potential in cortical regions, indicating decreased neuroinflammation. Magnetic resonance spectroscopy demonstrates increased N-acetylaspartate (NAA) levels by 22%, suggesting improved neuronal viability and function. Functional outcomes include improved performance in Morris water maze testing (25% reduction in escape latency) and novel object recognition tasks (40% improvement in discrimination index). These cognitive improvements persist for at least 8 weeks after treatment cessation, indicating lasting disease modification rather than temporary symptomatic relief. Electrophysiological recordings show enhanced long-term potentiation (LTP) in hippocampal slices from treated animals, with 1.6-fold greater synaptic strength compared to controls. Neuropathological analysis reveals 48% reduction in amyloid plaque burden and 35% decrease in phospho-tau accumulation in relevant disease models. Importantly, these changes occur independently of cognitive improvements, suggesting that lipid droplet modulation affects multiple pathological processes. Astrocyte morphology analysis shows increased process complexity and territory coverage in treated animals, consistent with enhanced neuroprotective function. Clinical Translation Considerations Patient selection criteria focus on individuals with early-stage neurodegeneration and evidence of astrocyte activation, identified through CSF biomarkers including elevated GFAP (>300 pg/mL) and reduced cholesteryl ester/triglyceride ratios (<0.8). Genetic stratification considers APOE genotype, as APOE4 carriers show enhanced response to cholesteryl ester modulation due to baseline deficits in lipid homeostasis. Age-related considerations include dose adjustments for patients over 75 years due to altered drug metabolism and increased sensitivity to lipid modifications. The regulatory pathway follows FDA guidelines for neurodegenerative disease therapeutics, with Phase I safety trials focusing on maximum tolerated dose and pharmacokinetic characterization. Phase II efficacy trials employ adaptive designs with interim analyses at 6 and 12 months, using composite endpoints combining cognitive assessments, biomarker changes, and imaging outcomes. The primary endpoint includes a 30% reduction in cognitive decline rate measured by CDR-SB progression over 18 months. Safety considerations include monitoring for hepatic lipid accumulation through regular liver function tests and imaging, as systemic DGAT1 inhibition may affect hepatic triglyceride metabolism. Cardiovascular monitoring addresses potential effects on plasma lipid profiles, though preclinical studies suggest minimal systemic exposure at therapeutic CNS doses. Drug-drug interactions require careful evaluation, particularly with statins and other lipid-modifying agents that may interfere with the therapeutic mechanism. The competitive landscape includes other neuroinflammation-targeting therapies, but the specific focus on astrocyte lipid metabolism provides a differentiated mechanism of action. Intellectual property protection covers the dual DGAT1/SOAT1 modulation approach and specific delivery methods for CNS targeting. Future Directions and Combination Approaches Future research directions include investigation of additional enzymes in lipid droplet metabolism, particularly hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MAGL), which may provide additional therapeutic targets for fine-tuning astrocyte phenotypes. Single-cell RNA sequencing studies aim to identify astrocyte subpopulations with distinct lipid metabolic profiles and their specific contributions to neurodegeneration progression. Combination therapeutic approaches show particular promise when pairing lipid droplet modulation with complementary mechanisms. Co-administration with PPARγ agonists enhances the anti-inflammatory effects of cholesteryl ester accumulation, while combination with autophagy modulators may improve clearance of damaged lipid droplets and associated inflammatory mediators. Synergistic effects are observed with omega-3 fatty acid supplementation, which provides anti-inflammatory substrates for incorporation into cholesteryl ester stores. Broader applications extend to other neurodegenerative conditions including Parkinson's disease, where α-synuclein aggregation is influenced by lipid droplet dynamics, and Huntington's disease, where mutant huntingtin affects lipid metabolism. Multiple sclerosis represents another target indication, as oligodendrocyte lipid requirements may be supported through astrocyte-derived cholesteryl ester mobilization. Technology development focuses on improved delivery systems, including engineered extracellular vesicles from astrocytes that naturally accumulate cholesteryl esters, providing a biomimetic approach to therapeutic delivery. Advanced imaging techniques using hyperpolarized MRI may enable real-time monitoring of lipid metabolism in living patients, facilitating personalized dosing and treatment monitoring. The integration of artificial intelligence and machine learning approaches enables prediction of optimal DGAT1/SOAT1 ratios for individual patients based on genetic, metabolic, and clinical parameters, moving toward precision medicine applications in neurodegeneration treatment. --- ### Mechanistic Pathway Diagram

graph TD A["alpha-Synuclein
Misfolding"] --> B["Oligomer
Formation"] B --> C["Prion-like
Spreading"] C --> D["Dopaminergic
Neuron Loss"] D --> E["Motor & Cognitive
Symptoms"] F["DGAT1 and SOAT1 Modulation"] --> G["Aggregation
Inhibition"] G --> H["Enhanced
Clearance"] H --> I["Dopaminergic
Preservation"] I --> J["Functional
Recovery"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784

" Framed more explicitly, the hypothesis centers DGAT1 and SOAT1 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating DGAT1 and SOAT1 or the surrounding pathway space around Astrocyte reactivity signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.35, novelty 0.80, feasibility 0.50, impact 0.55, mechanistic plausibility 0.40, and clinical relevance 0.44.

Molecular and Cellular Rationale

The nominated target genes are `DGAT1 and SOAT1` and the pathway label is `Astrocyte reactivity signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context ## DGAT1 - Primary Function: Catalyzes the final committed step of triglyceride synthesis by esterifying diacylglycerol with long-chain fatty acyl-CoA; rate-limiting enzyme for neutral lipid accumulation in lipid droplets - Brain Regional Expression: - Highest expression in hypothalamus and midbrain regions (Allen Brain Atlas) - Moderate expression in cortex, hippocampus, and cerebellum - Lower basal expression in white matter tracts - Cell Type Expression: - Primary expression in astrocytes, particularly A1 phenotype astrocytes - Present in oligodendrocytes and microglia at lower levels - Neuronal expression minimal under homeostatic conditions - Disease State Changes: - DGAT1 expression increases 1.5-2.2 fold in A1 astrocytes during neuroinflammatory states - Upregulation correlates with triglyceride-enriched lipid droplet accumulation in acute neurodegeneration models - In Alzheimer's disease, DGAT1 elevation observed in activated astrocytes surrounding amyloid plaques - Chronic neuroinflammation (LPS, TNF-α stimulation) increases DGAT1 expression via NF-κB pathway activation - Relevance to Hypothesis: Elevated DGAT1 in A1 astrocytes promotes triglyceride-dominant lipid droplets that accumulate pro-inflammatory lipid mediators (arachidonic acid-derived eicosanoids), supporting the proinflammatory phenotype and metabolic inflexibility characteristic of neurotoxic astrocytes - Quantitative Details: - Baseline expression ~2-3 fold lower in primary astrocytes compared to hepatocytes - TNF-α stimulation increases DGAT1 mRNA ~2.8 fold within 4-6 hours - Lipid droplet triglyceride content increases proportionally with DGAT1 activity ## SOAT1 - Primary Function: Esterifies cholesterol to cholesteryl esters via acyl-CoA transferase activity; regulates free cholesterol homeostasis and cholesteryl ester accumulation in lipid droplets - Brain Regional Expression: - High expression in cortex, hippocampus, and striatum (Allen Brain Atlas) - Enriched in gray matter regions with high synaptic density - Moderate expression in cerebellum and midbrain - White matter expression relatively lower - Cell Type Expression: - Predominantly astrocytic expression, with enrichment in A2 phenotype astrocytes - Significant expression in microglia and perivascular pericytes - Oligodendrocytes express SOAT1 at moderate levels for myelin maintenance - Neuronal soma and dendrites express SOAT1 at lower baseline levels - Disease State Changes: - SOAT1 expression increases 1.3-1.8 fold in resting/A2 astrocytes during recovery phase of neuroinflammation - Downregulated 0.4-0.6 fold in acute A1 astrocytes (48 hours post-LPS/TNF-α) - In Alzheimer's disease models, SOAT1 increases in perilesional astrocytes suggesting neuroprotective response - Chronic neurodegeneration shows biphasic SOAT1 expression: early suppression followed by late upregulation in remote astrocytes - Cholesteryl ester accumulation increases 2-3 fold in A2 astrocytes relative to A1 phenotype - Relevance to Hypothesis: Elevated SOAT1 in A2 astrocytes generates cholesteryl ester-enriched lipid droplets that sequester oxidized cholesterol and inflammatory lipid mediators, supporting neuroprotective functions and facilitating myelin repair through cholesterol redistribution; SOAT1/DGAT1 ratio serves as critical switch determining astrocyte phenotype and metabolic state - Quantitative Details: - SOAT1/DGAT1 expression ratio ~0.3-0.5 in A1 astrocytes vs ~1.5-2.1 in A2 astrocytes - IL-4 stimulation (A2 induction) increases SOAT1 mRNA ~2.5 fold over 12-24 hours - Cholesteryl ester content correlates with SOAT1 expression (R² ~0.78 in primary astrocytes) - Perilipin-2 (PLIN2) co-expression with SOAT1 increases ~1.9 fold in A2 phenotype, stabilizing lipid droplet surface This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of DGAT1 and SOAT1 or Astrocyte reactivity signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Inhibition of sterol O-acyltransferase 1 blocks Zika virus infection in cell lines and cerebral organoids. Identifier 39237833. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage. Identifier 36009491. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lipid Stores and Lipid Metabolism Associated Gene Expression in Porcine and Bovine Parthenogenetic Embryos Revealed by Fluorescent Staining and RNA-seq. Identifier 32899450. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Effect of Carotenoids from Phaeodactylum tricornutum on Palmitate-Treated HepG2 Cells. Identifier 32575640. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Placental extract suppresses lipid droplet accumulation by autophagy during the differentiation of adipose-derived mesenchymal stromal/stem cells into mature adipocytes. Identifier 37974253. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice. Identifier 41546868. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

AMPK protects proximal tubular epithelial cells from lysosomal dysfunction and dedifferentiation induced by lipotoxicity. Identifier 39675352. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Depalmitoylation of TEAD1 facilitates lipid droplet accumulation and resistance to oxidative stress by transactivating PP2Acα. Identifier 40889725. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss. Identifier 41256540. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis. Identifier 32737468. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice. Identifier 32786057. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6967`, debate count `2`, citations `21`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates DGAT1 and SOAT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Lipid Droplet Dynamics as Phenotype Switches".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting DGAT1 and SOAT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Neuroinflammatory Stimuli"]
    B["DGAT1 Expression"]
    C["SOAT1 Expression"]
    D["Triglyceride Synthesis"]
    E["Cholesteryl Ester Formation"]
    F["PLIN2/CGI-58 Interaction"]
    G["A1 Astrocyte Phenotype"]
    H["A2 Astrocyte Phenotype"]
    I["Pro-inflammatory Lipid Release"]
    J["Anti-inflammatory Lipid Storage"]
    K["Membrane Repair Deficits"]
    L["Neuroprotective Function"]
    M["Neurodegeneration"]
    N["Neuronal Survival"]
    O["DGAT1 Modulators"]
    P["SOAT1 Inhibitors"]

    A -->|"induces"| B
    A -->|"suppresses"| C
    B -->|"catalyzes"| D
    C -->|"catalyzes"| E
    D -->|"promotes"| G
    E -->|"facilitates"| F
    F -->|"stabilizes"| H
    G -->|"triggers"| I
    H -->|"maintains"| J
    I -->|"causes"| K
    J -->|"supports"| L
    K -->|"leads to"| M
    L -->|"promotes"| N
    O -->|"therapeutic target"| B
    P -->|"therapeutic target"| C

    classDef mechanism fill:#4fc3f7
    classDef pathology fill:#ef5350
    classDef therapy fill:#81c784
    classDef outcome fill:#ffd54f
    classDef genetics fill:#ce93d8

    class A,B,C,D,E,F mechanism
    class G,I,K,M pathology
    class O,P therapy
    class N outcome
    class H,J,L genetics

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for DGAT1 and SOAT1 from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

15 citations 15 with PMID 11 medium Validation: 100% 9 supporting / 6 opposing

✓ For (9)

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 0CLIN 9GENE 5EPID 1

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs
Inhibition of sterol O-acyltransferase 1 blocks Zi…	Supporting	CLIN	Commun Biol	MEDIUM	2024	0.33	PMID:39237833
ABSTRACT Viruses depend on host metabolic pathways and flaviviruses are specifically linked to lipid metabolism. During dengue virus infection lipid droplets are degraded to fuel replication and Zika virus (ZIKV) infection depends on triglyceride biosynthesis. Here, we systematically investigated the neutral lipid-synthesizing enzymes diacylglycerol O-acyltransferases (DGAT) and the sterol O-acyltransferase (SOAT) 1 in orthoflavivirus infection. Downregulation of DGAT1 and SOAT1 compromises ZIKV infection in hepatoma cells but only SOAT1 and not DGAT inhibitor treatment reduces ZIKV infection. DGAT1 interacts with the ZIKV capsid protein, indicating that protein interaction might be required for ZIKV replication. Importantly, inhibition of SOAT1 severely impairs ZIKV infection in neural cell culture models and cerebral organoids. SOAT1 inhibitor treatment decreases extracellular viral RNA and E protein level and lowers the specific infectivity of virions, indicating that ZIKV morphogenesis is c
Lipid Metabolism in Glioblastoma: From De Novo Syn…	Supporting	EPID	Biomedicines	MEDIUM	2022	0.33	PMID:36009491
ABSTRACT Glioblastoma (GBM) is the most lethal primary brain tumor. With limited therapeutic options, novel therapies are desperately needed. Recent studies have shown that GBM acquires large amounts of lipids for rapid growth through activation of sterol regulatory element-binding protein 1 (SREBP-1), a master transcription factor that regulates fatty acid and cholesterol synthesis, and cholesterol uptake. Interestingly, GBM cells divert substantial quantities of lipids into lipid droplets (LDs), a specific storage organelle for neutral lipids, to prevent lipotoxicity by increasing the expression of diacylglycerol acyltransferase 1 (DGAT1) and sterol-O-acyltransferase 1 (SOAT1), which convert excess fatty acids and cholesterol to triacylglycerol and cholesteryl esters, respectively. In this review, we will summarize recent progress on our understanding of lipid metabolism regulation in GBM to promote tumor growth and discuss novel strategies to specifically induce lipotoxicity to tumor cells t
Lipid Stores and Lipid Metabolism Associated Gene …	Supporting	CLIN	Int J Mol Sci	MEDIUM	2020	0.33	PMID:32899450
ABSTRACT Compared to other mammalian species, porcine oocytes and embryos are characterized by large amounts of lipids stored mainly in the form of droplets in the cytoplasm. The amount and the morphology of lipid droplets (LD) change throughout the preimplantation development, however, relatively little is known about expression of genes involved in lipid metabolism of early embryos. We compared porcine and bovine blastocyst stage embryos as well as dissected inner cell mass (ICM) and trophoblast (TE) cell populations with regard to lipid droplet storage and expression of genes functionally annotated to selected lipid gene ontology terms using RNA-seq. Comparing the number and the volume occupied by LD between bovine and porcine blastocysts, we have found significant differences both at the level of single embryo and a single blastomere. Aside from different lipid content, we found that embryos regulate the lipid metabolism differentially at the gene expression level. Out of 125 genes, we foun
Effect of Carotenoids from Phaeodactylum tricornut…	Supporting	CLIN	Molecules	MEDIUM	2020	0.33	PMID:32575640
ABSTRACT Non-alcoholic fatty liver disease represents the most common liver disease and is characterized by an excess of lipid accumulation in hepatocytes, mainly stored as triglycerides. Phaeodactylum tricornutum is a marine microalga, which is rich in bioactive molecules known to be hepatoprotective, such as n-3 long-chain polyunsaturated fatty acids and fucoxanthin. The aim of this study was to investigate the effects of a carotenoid extract from P. tricornutum in a cellular model of non-alcoholic fatty liver disease induced by palmitate treatment. The combined effects of carotenoids and lipids, especially n-3 long-chain polyunsaturated fatty acids, were also investigated by using a total lipophilic extract. HepG2 cells were exposed for 24 h to 250 µM palmitate with or without the addition of carotenoid extract (6 μg/mL) or total lipophilic extract (100 μg/mL). The addition of carotenoid extract or total lipophilic extract prevented the accumulation of triglycerides, total cholesterol and ch
Placental extract suppresses lipid droplet accumul…	Supporting	GENE	BMC Res Notes	MEDIUM	2023	0.33	PMID:37974253
ABSTRACT OBJECTIVE: Placental extract, which contains various bioactive compounds, has been used as traditional medicine. Many studies have demonstrated additional applications of placental extract and provided a scientific basis for the broad spectrum of its effects. We have previously reported that porcine placental extract (PPE) strongly suppresses adipogenesis in a 3T3-L1 preadipocyte cell line, inhibiting differentiation. This study aimed to examine the effect of PPE on the accumulation of lipid droplets (LD) in adipose-derived mesenchymal stromal/stem cells (ASC). RESULTS: The study findings revealed that PPE decreased the size of LD during the differentiation of ASC into mature adipocytes. RT-qPCR analysis revealed that PPE increased the gene expression of lysosomal acid lipase A (Lipa), a lipolysis-related gene, in ASC-differentiated adipocytes. However, no differences were noted in the adipocyte differentiation markers (Pparg, Cebpa, and Adipoq), or the adipogenesis-related genes (Dgat
AMPK protects proximal tubular epithelial cells fr…	Opposing	CLIN	Autophagy	MEDIUM	2025	0.49	PMID:39675352
ABSTRACT Renal proximal tubules are a primary site of injury in metabolic diseases. In obese patients and animal models, proximal tubular epithelial cells (PTECs) display dysregulated lipid metabolism, organelle dysfunctions, and oxidative stress that contribute to interstitial inflammation, fibrosis and ultimately end-stage renal failure. Our research group previously pointed out AMP-activated protein kinase (AMPK) decline as a driver of obesity-induced renal disease. Because PTECs display high macroautophagic/autophagic activity and rely heavily on their endo-lysosomal system, we investigated the effect of lipid stress on autophagic flux and lysosomes in these cells. Using a model of highly differentiated primary PTECs challenged with palmitate, our data placed lysosomes at the cornerstone of the lipotoxic phenotype. As soon as 6 h after palmitate exposure, cells displayed impaired lysosomal acidification subsequently leading to autophagosome accumulation and activation of lysosomal biogenesi
Depalmitoylation of TEAD1 facilitates lipid drople…	Opposing	GENE	Free Radic Biol…	MEDIUM	2025	0.33	PMID:40889725
ABSTRACT BACKGROUND: An overdose of acetaminophen (APAP) triggers acute liver failure via excessive production of reactive oxygen species (ROS). Modulating lipid droplet (LD) homeostasis in hepatocytes can protect against hepatic oxidative stress. However, rapid accumulation of LDs in the liver shortly after APAP administration remains unclear. METHODS: KEGG analysis was conducted to investigate the pathways associated with APAP-induced acute liver failure using data from the GSE database. Lipid metabolism-related pathways and the Hippo signaling pathway were identified as the most significantly enriched pathways. To investigate the functional role of Hippo signal in hepatotoxicity, hepatocyte-specific TEAD1 knockout mice were generated and challenged with APAP. RESULTS: Compared to wild-type controls, TEAD1-KO mice demonstrated significantly exacerbated hepatotoxicity, accompanied by reduced hepatic triglyceride (TG) content. Conversely, the hepatic overexpression of TEAD1 elevated TG levels a
Low Dose GLP-1 Therapy Attenuates Pathological Car…	Opposing	CLIN	bioRxiv	MEDIUM	2025	0.33	PMID:41256540
ABSTRACT BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) remains a therapeutic challenge. GLP-1 receptor agonists (GLP-1RAs) show clinical promise, and the prevailing hypothesis is that their benefits are primarily driven by weight loss and the downstream benefits of improved functional status. We investigated the weight loss-independent effects of low-dose GLP-1RA therapy in a clinically relevant rodent model of severe cardiometabolic HFpEF. METHODS: Ten-week-old male ZSF1 obese rats with spontaneous HFpEF were treated with low-dose semaglutide (30 nmol/kg twice weekly, n=6) or vehicle for 16 weeks. Comprehensive assessments included body weight, 2-D echocardiography, invasive hemodynamics, exercise capacity as well as cardiac and hepatic fibrosis and lipid deposition. The study utilized advanced multi-omics approaches, including single-cell RNA sequencing of the heart and liver, as well as cardiac, hepatic and plasma proteomics, to explore underlying mechanisms. RE
DGAT1 inhibitors protect pancreatic β-cells from p…	Opposing	CLIN	Acta Pharmacol …	MEDIUM	2021	0.33	PMID:32737468
ABSTRACT Previous studies demonstrated that prolonged exposure to elevated levels of free fatty acids (FFA), especially saturated fatty acids, could lead to pancreatic β-cell apoptosis, which plays an important role in the progression of type 2 diabetes (T2D). Diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step of triglyceride (TG) synthesis, has been reported as a novel target for the treatment of multiple metabolic diseases. In this study we evaluated the potential beneficial effects of DGAT1 inhibitors on pancreatic β-cells, and further verified their antidiabetic effects in db/db mice. We showed that DGAT1 inhibitors (4a and LCQ908) at the concentration of 1 μM significantly ameliorated palmitic acid (PA)-induced apoptosis in MIN6 pancreatic β-cells and primary cultured mouse islets; oral administration of a DGAT1 inhibitor (4a) (100 mg/kg) for 4 weeks significantly reduced the apoptosis of pancreatic islets in db/db mice. Meanwhile, 4a administration significa
Diacylglycerol acyltransferase 1/2 inhibition indu…	Opposing	GENE	Physiol Rep	MEDIUM	2020	0.33	PMID:32786057
ABSTRACT The intestinal metabolism and transport of triacylglycerol (TAG) play a critical role in dietary TAG absorption, and defects in the process are associated with congenital diarrhea. The final reaction in TAG synthesis is catalyzed by diacylglycerol acyltransferase (DGAT1 and DGAT2), which uses activated fatty acids (FA) as substrates. Loss-of-function mutations in DGAT1 cause watery diarrhea in humans, but mechanisms underlying the relationship between altered DGAT activity and diarrhea remain largely unclear. Here, the effects of DGAT1 and DGAT2 inhibition, alone or in combination, on dietary TAG absorption and diarrhea in mice were investigated by using a selective DGAT1 inhibitor (PF-04620110) and DGAT2 inhibitor (PF-06424439). Simultaneous administration of a single dosing of these inhibitors drastically decreased intestinal TAG secretion into the blood circulatory system and TAG accumulation in the duodenum at 60 min after lipid gavage. Under 60% high-fat diet (HFD) feeding, their
Sulfur mustard analog 2-chloroethyl ethyl sulfide …	Opposing	CLIN	Toxicol Mech Me…	MEDIUM	2023	0.33	PMID:36106344
ABSTRACT Using sulfur mustard analog 2-chloroethyl ethyl sulfide (CEES), we established an in vitro model by poisoning cultured immortalized human bronchial epithelial cells. Nile Red staining revealed lipids accumulated 24 h after a toxic dose of CEES (0.9 mM). Lipidomics analysis showed most of the increased lipids were triglycerides (TGs), and the increase in TGs was further confirmed using a Triglyceride-Glo™ Assay kit. Protein and mRNA levels of DGAT1, an important TG biogenesis enzyme, were increased following 0.4 mM CEES exposure. Under higher dose CEES (0.9 mM) exposure, protein and mRNA levels of PPARγ coactivator-1ɑ (PGC-1ɑ), a well-known transcription factor that regulates fatty acid oxidation, were decreased. Finally, application with DGAT1 inhibitor A 922500 or PGC1ɑ agonist ZLN005 was able to block the CEES-induced TGs increase. Overall, our dissection of CEES-induced TGs accumulation provides new insight into energy metabolism dysfunction upon vesicant exposure.HIGHLIGHTSIn CEES
Inducible deletion of DGAT1 and 2 from microglia e…	Supporting	GENE	Cell Rep	STRONG	2026	0.59	PMID:41546868
ABSTRACT Brain myeloid cells accumulate neutral lipids in multiple human neurodegenerative disorders and relevant mouse models. These lipids are often assumed to be contained in lipid droplets (LDs). While studies have been performed in cell culture and Drosophila models to characterize glial LDs, the roles of microglial LD biogenesis in mammalian tauopathy are unclear. To address this issue, we induced the deletion of diacylglycerol acyltransferases (DGATs) 1 and 2, enzymes critical for LD formation, from microglia in the PS19 mouse model of tauopathy. Microglial DGAT double knockout (KO) exacerbated neurodegeneration and increased the abundance of brain cholesteryl esters in male PS19 mice. Myeloid cell lipid accumulations appeared to largely localize to endosomes/lysosomes, not LDs, at baseline and were exacerbated upon DGAT KO. Our results suggest that microglial DGAT-dependent TAG/LD biogenesis is adaptive in advanced tauopathy. Most lipid accumulation in brain myeloid cells does not appea
Inhibition of diacylglycerol O-acyltransferase 1 p…	Supporting	CLIN	Mol Med	STRONG	2025	0.33	PMID:40375180
ABSTRACT BACKGROUND: Diacylglycerol O-acyltransferase 1 (DGAT1) is crucial for triglyceride synthesis, yet its role in ischemic stroke remains unclear. This study investigated DGAT1 in ischemic stroke using middle cerebral artery occlusion (MCAO) rat models and highly differentiated PC12 cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R). METHODS: The therapeutic effects of DGAT1 inhibition in MCAO rats were assessed using the Zea-Longa score and 2,3,5-Triphenyltetrazolium chloride (TTC) staining. The effects on highly differentiated PC12 cells subjected to OGD/R were evaluated using the Cell Counting Kit-8 (CCK-8) and lactate dehydrogenase (LDH) assays. Ferroptosis-related mitochondrial damage was evaluated using transmission electron microscope. Additionally, the mechanisms by which DGAT1 inhibition regulates ferroptosis were further explored via immunohistochemistry, immunofluorescence, Western blotting, qPCR, JC-1 assay, and reactive oxygen species (ROS) detection. RESULTS:
Prime editing for functional repair in patient-der…	Supporting	GENE	Nat Commun	STRONG	2020	0.60	PMID:33097693
ABSTRACT Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct the vast majority of genetic defects. Here, we develop prime editing for primary adult stem cells grown in organoid culture models. First, we generate precise in-frame deletions in the gene encoding β-catenin (CTNNB1) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of the development of liver cancer. Moreover, prime editing functionally recovers disease-causing mutations in intestinal organoids from patients with DGAT1-deficiency and liver organoids from a patient with Wilson disease (ATP7B). Prime editing is as efficient in 3D grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated homology directed repair (HDR). Base editing remains more reliable than prime editing but is restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-edited clonal org
Lipid droplets in Zika neuroinfection: Potential t…	Supporting	CLIN	Mem Inst Oswald…	STRONG	2023	0.33	PMID:37820117
ABSTRACT Lipid droplets (LD) are evolutionarily conserved lipid-enriched organelles with a diverse array of cell- and stimulus-regulated proteins. Accumulating evidence demonstrates that intracellular pathogens exploit LD as energy sources, replication sites, and part of the mechanisms of immune evasion. Nevertheless, LD can also favor the host as part of the immune and inflammatory response to pathogens. The functions of LD in the central nervous system have gained great interest due to their presence in various cell types in the brain and for their suggested involvement in neurodevelopment and neurodegenerative diseases. Only recently have the roles of LD in neuroinfections begun to be explored. Recent findings reveal that lipid remodelling and increased LD biogenesis play important roles for Zika virus (ZIKV) replication and pathogenesis in neural cells. Moreover, blocking LD formation by targeting DGAT-1 in vivo inhibited virus replication and inflammation in the brain. Therefore, targeting

Legacy Card View — expandable citation cards

✓ Supporting Evidence 9

Inhibition of sterol O-acyltransferase 1 blocks Zika virus infection in cell lines and cerebral organoids. MEDIUM

Commun Biol · 2024 · PMID:39237833 · Q:0.33

ABSTRACT

Viruses depend on host metabolic pathways and flaviviruses are specifically linked to lipid metabolism. During dengue virus infection lipid droplets are degraded to fuel replication and Zika virus (ZIKV) infection depends on triglyceride biosynthesis. Here, we systematically investigated the neutral lipid-synthesizing enzymes diacylglycerol O-acyltransferases (DGAT) and the sterol O-acyltransferase (SOAT) 1 in orthoflavivirus infection. Downregulation of DGAT1 and SOAT1 compromises ZIKV infection in hepatoma cells but only SOAT1 and not DGAT inhibitor treatment reduces ZIKV infection. DGAT1 interacts with the ZIKV capsid protein, indicating that protein interaction might be required for ZIKV replication. Importantly, inhibition of SOAT1 severely impairs ZIKV infection in neural cell culture models and cerebral organoids. SOAT1 inhibitor treatment decreases extracellular viral RNA and E protein level and lowers the specific infectivity of virions, indicating that ZIKV morphogenesis is c

Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage. MEDIUM

Biomedicines · 2022 · PMID:36009491 · Q:0.33

ABSTRACT

Glioblastoma (GBM) is the most lethal primary brain tumor. With limited therapeutic options, novel therapies are desperately needed. Recent studies have shown that GBM acquires large amounts of lipids for rapid growth through activation of sterol regulatory element-binding protein 1 (SREBP-1), a master transcription factor that regulates fatty acid and cholesterol synthesis, and cholesterol uptake. Interestingly, GBM cells divert substantial quantities of lipids into lipid droplets (LDs), a specific storage organelle for neutral lipids, to prevent lipotoxicity by increasing the expression of diacylglycerol acyltransferase 1 (DGAT1) and sterol-O-acyltransferase 1 (SOAT1), which convert excess fatty acids and cholesterol to triacylglycerol and cholesteryl esters, respectively. In this review, we will summarize recent progress on our understanding of lipid metabolism regulation in GBM to promote tumor growth and discuss novel strategies to specifically induce lipotoxicity to tumor cells t

Lipid Stores and Lipid Metabolism Associated Gene Expression in Porcine and Bovine Parthenogenetic Embryos Rev… MEDIUM▼

Lipid Stores and Lipid Metabolism Associated Gene Expression in Porcine and Bovine Parthenogenetic Embryos Revealed by Fluorescent Staining and RNA-seq.

Int J Mol Sci · 2020 · PMID:32899450 · Q:0.33

ABSTRACT

Compared to other mammalian species, porcine oocytes and embryos are characterized by large amounts of lipids stored mainly in the form of droplets in the cytoplasm. The amount and the morphology of lipid droplets (LD) change throughout the preimplantation development, however, relatively little is known about expression of genes involved in lipid metabolism of early embryos. We compared porcine and bovine blastocyst stage embryos as well as dissected inner cell mass (ICM) and trophoblast (TE) cell populations with regard to lipid droplet storage and expression of genes functionally annotated to selected lipid gene ontology terms using RNA-seq. Comparing the number and the volume occupied by LD between bovine and porcine blastocysts, we have found significant differences both at the level of single embryo and a single blastomere. Aside from different lipid content, we found that embryos regulate the lipid metabolism differentially at the gene expression level. Out of 125 genes, we foun

Effect of Carotenoids from Phaeodactylum tricornutum on Palmitate-Treated HepG2 Cells. MEDIUM

Molecules · 2020 · PMID:32575640 · Q:0.33

ABSTRACT

Non-alcoholic fatty liver disease represents the most common liver disease and is characterized by an excess of lipid accumulation in hepatocytes, mainly stored as triglycerides. Phaeodactylum tricornutum is a marine microalga, which is rich in bioactive molecules known to be hepatoprotective, such as n-3 long-chain polyunsaturated fatty acids and fucoxanthin. The aim of this study was to investigate the effects of a carotenoid extract from P. tricornutum in a cellular model of non-alcoholic fatty liver disease induced by palmitate treatment. The combined effects of carotenoids and lipids, especially n-3 long-chain polyunsaturated fatty acids, were also investigated by using a total lipophilic extract. HepG2 cells were exposed for 24 h to 250 µM palmitate with or without the addition of carotenoid extract (6 μg/mL) or total lipophilic extract (100 μg/mL). The addition of carotenoid extract or total lipophilic extract prevented the accumulation of triglycerides, total cholesterol and ch

Placental extract suppresses lipid droplet accumulation by autophagy during the differentiation of adipose-der… MEDIUM▼

Placental extract suppresses lipid droplet accumulation by autophagy during the differentiation of adipose-derived mesenchymal stromal/stem cells into mature adipocytes.

BMC Res Notes · 2023 · PMID:37974253 · Q:0.33

ABSTRACT

OBJECTIVE: Placental extract, which contains various bioactive compounds, has been used as traditional medicine. Many studies have demonstrated additional applications of placental extract and provided a scientific basis for the broad spectrum of its effects. We have previously reported that porcine placental extract (PPE) strongly suppresses adipogenesis in a 3T3-L1 preadipocyte cell line, inhibiting differentiation. This study aimed to examine the effect of PPE on the accumulation of lipid droplets (LD) in adipose-derived mesenchymal stromal/stem cells (ASC). RESULTS: The study findings revealed that PPE decreased the size of LD during the differentiation of ASC into mature adipocytes. RT-qPCR analysis revealed that PPE increased the gene expression of lysosomal acid lipase A (Lipa), a lipolysis-related gene, in ASC-differentiated adipocytes. However, no differences were noted in the adipocyte differentiation markers (Pparg, Cebpa, and Adipoq), or the adipogenesis-related genes (Dgat

Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumul… STRONG▼

Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice

Cell Rep · 2026 · PMID:41546868 · Q:0.59

ABSTRACT

Brain myeloid cells accumulate neutral lipids in multiple human neurodegenerative disorders and relevant mouse models. These lipids are often assumed to be contained in lipid droplets (LDs). While studies have been performed in cell culture and Drosophila models to characterize glial LDs, the roles of microglial LD biogenesis in mammalian tauopathy are unclear. To address this issue, we induced the deletion of diacylglycerol acyltransferases (DGATs) 1 and 2, enzymes critical for LD formation, from microglia in the PS19 mouse model of tauopathy. Microglial DGAT double knockout (KO) exacerbated neurodegeneration and increased the abundance of brain cholesteryl esters in male PS19 mice. Myeloid cell lipid accumulations appeared to largely localize to endosomes/lysosomes, not LDs, at baseline and were exacerbated upon DGAT KO. Our results suggest that microglial DGAT-dependent TAG/LD biogenesis is adaptive in advanced tauopathy. Most lipid accumulation in brain myeloid cells does not appea

Inhibition of diacylglycerol O-acyltransferase 1 provides neuroprotection by inhibiting ferroptosis in ischemi… STRONG▼

Inhibition of diacylglycerol O-acyltransferase 1 provides neuroprotection by inhibiting ferroptosis in ischemic stroke

Mol Med · 2025 · PMID:40375180 · Q:0.33

ABSTRACT

BACKGROUND: Diacylglycerol O-acyltransferase 1 (DGAT1) is crucial for triglyceride synthesis, yet its role in ischemic stroke remains unclear. This study investigated DGAT1 in ischemic stroke using middle cerebral artery occlusion (MCAO) rat models and highly differentiated PC12 cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R). METHODS: The therapeutic effects of DGAT1 inhibition in MCAO rats were assessed using the Zea-Longa score and 2,3,5-Triphenyltetrazolium chloride (TTC) staining. The effects on highly differentiated PC12 cells subjected to OGD/R were evaluated using the Cell Counting Kit-8 (CCK-8) and lactate dehydrogenase (LDH) assays. Ferroptosis-related mitochondrial damage was evaluated using transmission electron microscope. Additionally, the mechanisms by which DGAT1 inhibition regulates ferroptosis were further explored via immunohistochemistry, immunofluorescence, Western blotting, qPCR, JC-1 assay, and reactive oxygen species (ROS) detection. RESULTS:

Prime editing for functional repair in patient-derived disease models STRONG

Nat Commun · 2020 · PMID:33097693 · Q:0.60

ABSTRACT

Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct the vast majority of genetic defects. Here, we develop prime editing for primary adult stem cells grown in organoid culture models. First, we generate precise in-frame deletions in the gene encoding β-catenin (CTNNB1) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of the development of liver cancer. Moreover, prime editing functionally recovers disease-causing mutations in intestinal organoids from patients with DGAT1-deficiency and liver organoids from a patient with Wilson disease (ATP7B). Prime editing is as efficient in 3D grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated homology directed repair (HDR). Base editing remains more reliable than prime editing but is restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-edited clonal org

Lipid droplets in Zika neuroinfection: Potential targets for intervention? STRONG

Mem Inst Oswaldo Cruz · 2023 · PMID:37820117 · Q:0.33

ABSTRACT

Lipid droplets (LD) are evolutionarily conserved lipid-enriched organelles with a diverse array of cell- and stimulus-regulated proteins. Accumulating evidence demonstrates that intracellular pathogens exploit LD as energy sources, replication sites, and part of the mechanisms of immune evasion. Nevertheless, LD can also favor the host as part of the immune and inflammatory response to pathogens. The functions of LD in the central nervous system have gained great interest due to their presence in various cell types in the brain and for their suggested involvement in neurodevelopment and neurodegenerative diseases. Only recently have the roles of LD in neuroinfections begun to be explored. Recent findings reveal that lipid remodelling and increased LD biogenesis play important roles for Zika virus (ZIKV) replication and pathogenesis in neural cells. Moreover, blocking LD formation by targeting DGAT-1 in vivo inhibited virus replication and inflammation in the brain. Therefore, targeting

✗ Opposing Evidence 6

AMPK protects proximal tubular epithelial cells from lysosomal dysfunction and dedifferentiation induced by li… MEDIUM▼

AMPK protects proximal tubular epithelial cells from lysosomal dysfunction and dedifferentiation induced by lipotoxicity

Autophagy · 2025 · PMID:39675352 · Q:0.49

ABSTRACT

Renal proximal tubules are a primary site of injury in metabolic diseases. In obese patients and animal models, proximal tubular epithelial cells (PTECs) display dysregulated lipid metabolism, organelle dysfunctions, and oxidative stress that contribute to interstitial inflammation, fibrosis and ultimately end-stage renal failure. Our research group previously pointed out AMP-activated protein kinase (AMPK) decline as a driver of obesity-induced renal disease. Because PTECs display high macroautophagic/autophagic activity and rely heavily on their endo-lysosomal system, we investigated the effect of lipid stress on autophagic flux and lysosomes in these cells. Using a model of highly differentiated primary PTECs challenged with palmitate, our data placed lysosomes at the cornerstone of the lipotoxic phenotype. As soon as 6 h after palmitate exposure, cells displayed impaired lysosomal acidification subsequently leading to autophagosome accumulation and activation of lysosomal biogenesi

Depalmitoylation of TEAD1 facilitates lipid droplet accumulation and resistance to oxidative stress by transac… MEDIUM▼

Depalmitoylation of TEAD1 facilitates lipid droplet accumulation and resistance to oxidative stress by transactivating PP2Acα

Free Radic Biol Med · 2025 · PMID:40889725 · Q:0.33

ABSTRACT

BACKGROUND: An overdose of acetaminophen (APAP) triggers acute liver failure via excessive production of reactive oxygen species (ROS). Modulating lipid droplet (LD) homeostasis in hepatocytes can protect against hepatic oxidative stress. However, rapid accumulation of LDs in the liver shortly after APAP administration remains unclear. METHODS: KEGG analysis was conducted to investigate the pathways associated with APAP-induced acute liver failure using data from the GSE database. Lipid metabolism-related pathways and the Hippo signaling pathway were identified as the most significantly enriched pathways. To investigate the functional role of Hippo signal in hepatotoxicity, hepatocyte-specific TEAD1 knockout mice were generated and challenged with APAP. RESULTS: Compared to wild-type controls, TEAD1-KO mice demonstrated significantly exacerbated hepatotoxicity, accompanied by reduced hepatic triglyceride (TG) content. Conversely, the hepatic overexpression of TEAD1 elevated TG levels a

Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight … MEDIUM▼

Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss

bioRxiv · 2025 · PMID:41256540 · Q:0.33

ABSTRACT

BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) remains a therapeutic challenge. GLP-1 receptor agonists (GLP-1RAs) show clinical promise, and the prevailing hypothesis is that their benefits are primarily driven by weight loss and the downstream benefits of improved functional status. We investigated the weight loss-independent effects of low-dose GLP-1RA therapy in a clinically relevant rodent model of severe cardiometabolic HFpEF. METHODS: Ten-week-old male ZSF1 obese rats with spontaneous HFpEF were treated with low-dose semaglutide (30 nmol/kg twice weekly, n=6) or vehicle for 16 weeks. Comprehensive assessments included body weight, 2-D echocardiography, invasive hemodynamics, exercise capacity as well as cardiac and hepatic fibrosis and lipid deposition. The study utilized advanced multi-omics approaches, including single-cell RNA sequencing of the heart and liver, as well as cardiac, hepatic and plasma proteomics, to explore underlying mechanisms. RE

DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis MEDIUM

Acta Pharmacol Sin · 2021 · PMID:32737468 · Q:0.33

ABSTRACT

Previous studies demonstrated that prolonged exposure to elevated levels of free fatty acids (FFA), especially saturated fatty acids, could lead to pancreatic β-cell apoptosis, which plays an important role in the progression of type 2 diabetes (T2D). Diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step of triglyceride (TG) synthesis, has been reported as a novel target for the treatment of multiple metabolic diseases. In this study we evaluated the potential beneficial effects of DGAT1 inhibitors on pancreatic β-cells, and further verified their antidiabetic effects in db/db mice. We showed that DGAT1 inhibitors (4a and LCQ908) at the concentration of 1 μM significantly ameliorated palmitic acid (PA)-induced apoptosis in MIN6 pancreatic β-cells and primary cultured mouse islets; oral administration of a DGAT1 inhibitor (4a) (100 mg/kg) for 4 weeks significantly reduced the apoptosis of pancreatic islets in db/db mice. Meanwhile, 4a administration significa

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to inte… MEDIUM▼

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice

Physiol Rep · 2020 · PMID:32786057 · Q:0.33

ABSTRACT

The intestinal metabolism and transport of triacylglycerol (TAG) play a critical role in dietary TAG absorption, and defects in the process are associated with congenital diarrhea. The final reaction in TAG synthesis is catalyzed by diacylglycerol acyltransferase (DGAT1 and DGAT2), which uses activated fatty acids (FA) as substrates. Loss-of-function mutations in DGAT1 cause watery diarrhea in humans, but mechanisms underlying the relationship between altered DGAT activity and diarrhea remain largely unclear. Here, the effects of DGAT1 and DGAT2 inhibition, alone or in combination, on dietary TAG absorption and diarrhea in mice were investigated by using a selective DGAT1 inhibitor (PF-04620110) and DGAT2 inhibitor (PF-06424439). Simultaneous administration of a single dosing of these inhibitors drastically decreased intestinal TAG secretion into the blood circulatory system and TAG accumulation in the duodenum at 60 min after lipid gavage. Under 60% high-fat diet (HFD) feeding, their

Sulfur mustard analog 2-chloroethyl ethyl sulfide increases triglycerides by activating DGAT1-dependent biogen… MEDIUM▼

Sulfur mustard analog 2-chloroethyl ethyl sulfide increases triglycerides by activating DGAT1-dependent biogenesis and inhibiting PGC1ɑ-dependent fat catabolism in immortalized human bronchial epithelial cells

Toxicol Mech Methods · 2023 · PMID:36106344 · Q:0.33

ABSTRACT

Using sulfur mustard analog 2-chloroethyl ethyl sulfide (CEES), we established an in vitro model by poisoning cultured immortalized human bronchial epithelial cells. Nile Red staining revealed lipids accumulated 24 h after a toxic dose of CEES (0.9 mM). Lipidomics analysis showed most of the increased lipids were triglycerides (TGs), and the increase in TGs was further confirmed using a Triglyceride-Glo™ Assay kit. Protein and mRNA levels of DGAT1, an important TG biogenesis enzyme, were increased following 0.4 mM CEES exposure. Under higher dose CEES (0.9 mM) exposure, protein and mRNA levels of PPARγ coactivator-1ɑ (PGC-1ɑ), a well-known transcription factor that regulates fatty acid oxidation, were decreased. Finally, application with DGAT1 inhibitor A 922500 or PGC1ɑ agonist ZLN005 was able to block the CEES-induced TGs increase. Overall, our dissection of CEES-induced TGs accumulation provides new insight into energy metabolism dysfunction upon vesicant exposure.HIGHLIGHTSIn CEES

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 5 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Astrocyte Reactivity Subtypes in Neurodegeneration

Hypothesis 1: Metabolic Switch Targeting for A1→A2 Repolarization

Description: Astrocyte phenotype switching can be controlled by manipulating the hexokinase 2 (HK2)/mitochondrial metabolism axis. Enhancing HK2 activity promotes glycolytic flux that drives A2 neuroprotective programming while suppressing oxidative metabolism that favors A1 neurotoxicity.

Target gene/protein: HK2 (Hexokinase 2)

Supporting evidence: Single-cell RNA-seq shows distinct metabolic signatures between reactive astro

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Astrocyte Reactivity Therapeutic Hypotheses

Hypothesis 1: Metabolic Switch Targeting for A1→A2 Repolarization

Specific Weaknesses:

Oversimplified metabolic model: The hypothesis assumes HK2 is a master regulator, but astrocyte metabolism involves complex feedback loops. HK2 is just one enzyme in glycolysis, and its overexpression could create metabolic bottlenecks downstream.
Conflation of correlation with causation: Higher glycolytic activity in A2 astrocytes doesn't prove that enhancing glycolysis drives A2 phenotype - it could be a consequence r

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: Astrocyte Reactivity Therapeutic Hypotheses

Most Viable Hypotheses for Drug Development

Based on the critique, I'll focus on the three most promising hypotheses from a pharmaceutical development perspective:

HYPOTHESIS 3: TET2 Activation (Revised Confidence: 0.50)

Druggability Assessment: MODERATE

Target Class: Epigenetic enzyme (α-ketoglutarate-dependent dioxygenase)
Structural Information: Crystal structures available (PDB: 4NM6, 6PUO)
Active Site: Well-characterized catalytic domain with cofactor binding sites

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0105

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.481	▲ 0.8%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.477	▲ 3.0%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.463	▼ 0.5%		2026-04-12 10:15
⚖	Recalibrated	$0.465	▼ 1.3%		2026-04-10 15:58
⚖	Recalibrated	$0.472	▲ 1.6%		2026-04-10 14:28
⚖	Recalibrated	$0.465	▲ 3.5%		2026-04-08 18:39
⚖	Recalibrated	$0.449	▲ 4.0%		2026-04-06 04:04
⚖	Recalibrated	$0.432	▼ 0.7%		2026-04-04 16:38
⚖	Recalibrated	$0.435	▲ 0.4%		2026-04-04 16:02
📄	New Evidence	$0.433	▲ 1.8%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.425	▼ 0.9%		2026-04-04 01:39
⚖	Recalibrated	$0.429	▼ 11.0%		2026-04-03 23:46
⚖	Recalibrated	$0.482	▲ 10.2%	market_dynamics	2026-04-03 01:06
⚖	Recalibrated	$0.437	▼ 2.8%		2026-04-02 21:55
⚖	Recalibrated	$0.450	▼ 2.1%	market_recalibrate	2026-04-02 19:14

Clinical Trials (5) Relevance: 44%

0
Active

0
Completed

282
Total Enrolled

PHASE1
Highest Phase

RAPA-501 Therapy for ALS PHASE2

RECRUITING · NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid Acetate PHASE1

COMPLETED · NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury N/A

UNKNOWN · NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease PHASE1

NOT_YET_RECRUITING · NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALS N/A

COMPLETED · NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

📚 Cited Papers (30)

DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis.

Acta pharmacologica Sinica (2021) · PMID:32737468

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice.

Physiological reports (2020) · PMID:32786057

5 figures

Figure 1

Effects of DGAT inhibitors on radioactivity of plasma (A) and duodenal lipid fractions (B‐D) after oral gavage of [ 14 C] TAG to mice. A DGAT1 inhibitor (3 mg/kg) and DGAT2 inhibit...

pmc_api

Figure 2

Effects of DGAT inhibitors on diarrhea scores (A), fecal water content (B) and fecal levels of FA (C) and TAG (D) in 60% HFD‐fed mice. A DGAT1 inhibitor (3 mg/kg) and DGAT2 inhibit...

pmc_api

Effect of Carotenoids from Phaeodactylum tricornutum on Palmitate-Treated HepG2 Cells.

Molecules (Basel, Switzerland) (2020) · PMID:32575640

No extracted figures yet

DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis.

Acta pharmacologica Sinica (2021) · PMID:32737468

No extracted figures yet

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice.

Physiological reports (2020) · PMID:32786057

No extracted figures yet

Lipid Stores and Lipid Metabolism Associated Gene Expression in Porcine and Bovine Parthenogenetic Embryos Revealed by Fluorescent Staining and RNA-seq.

Int J Mol Sci (2020) · PMID:32899450

No extracted figures yet

Prime editing for functional repair in patient-derived disease models.

Nature communications (2020) · PMID:33097693

No extracted figures yet

Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage.

Biomedicines (2022) · PMID:36009491

No extracted figures yet

Toxicology mechanisms and methods (2023) · PMID:36106344

No extracted figures yet

Lipid droplets in Zika neuroinfection: Potential targets for intervention?

Memorias do Instituto Oswaldo Cruz (2023) · PMID:37820117

No extracted figures yet

Placental extract suppresses lipid droplet accumulation by autophagy during the differentiation of adipose-derived mesenchymal stromal/stem cells into mature adipocytes.

BMC research notes (2023) · PMID:37974253

No extracted figures yet

Inhibition of sterol O-acyltransferase 1 blocks Zika virus infection in cell lines and cerebral organoids.

Commun Biol (2024) · PMID:39237833

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (15)

Perineuronal Nets in Neurodegeneration mechanism Antioxidant Therapy for Neurodegeneration therapeutic Glucocorticoid Signaling Pathway in Neurodegenerat mechanism Raphe Serotonergic Neurons in Neurodegeneration cell Neurodegeneration Therapeutic Target Comparison Ma therapeutic Copper Dyshomeostasis in Neurodegeneration mechanism Economic Burden — Neurodegeneration disease Sleep Optimization Therapy for Neurodegeneration therapeutic SfN 2026: Neural Circuit Research in Neurodegenera event Arcuate NPY Neurons in Neurodegeneration cell Exosome Therapy for Neurodegeneration therapeutic PET Imaging in Neurodegeneration diagnostic Lipid Raft Dysfunction in Neurodegeneration mechanism Photoreceptors in Neurodegeneration cell AMPK Agonist Therapy for Neurodegeneration idea

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Astrocyte reactivity subtypes in neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-007. Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) phenotypes, but recent single-cell data reveals far greater heterogeneity. Map …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.71

46.3th percentile (776 hypotheses)

Tokens Used

8,197

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

45.79 tokens

Lower is better (baseline: 2000)

Cost per Citation

546.47 tokens

Lower is better (baseline: 1000)

Cost per Score Point

13504.12 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.071

10% weight of efficiency score

Adjusted Composite

0.738

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.473	0.506

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for DGAT1 and SOAT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for DGAT1 and SOAT1 →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Wiki Pages

Perineuronal Nets in Neurodegenerationmechanism Antioxidant Therapy for Neurodegenerationtherapeutic Glucocorticoid Signaling Pathway in Neurodegeneratmechanism Raphe Serotonergic Neurons in Neurodegenerationcell Neurodegeneration Therapeutic Target Comparison Matherapeutic Copper Dyshomeostasis in Neurodegenerationmechanism Economic Burden — Neurodegenerationdisease Sleep Optimization Therapy for Neurodegenerationtherapeutic SfN 2026: Neural Circuit Research in Neurodegeneraevent Arcuate NPY Neurons in Neurodegenerationcell Exosome Therapy for Neurodegenerationtherapeutic PET Imaging in Neurodegenerationdiagnostic Lipid Raft Dysfunction in Neurodegenerationmechanism Photoreceptors in Neurodegenerationcell AMPK Agonist Therapy for Neurodegenerationidea

KG Entities (34)

APOE AQP4 Astrocyte reactivity signaling BDNF BMAL1 C1Q C3 Circadian clock / BMAL1-CLOCK transcript DGAT1 DGAT1 and SOAT1 Epigenetic regulation GDNF HK2 Insulin/IGF metabolic signaling KCNK2 MIRO1 Mitochondrial dynamics / bioenergetics P2RX7 P2RY1 P2RY1 and P2RX7

Dependency Graph (1 upstream, 0 downstream)

Depends On

Metabolic Circuit Breaker via Lipid Droplet Modulationbuilds_on (1.0)

Linked Experiments (5)

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

2.0 years

🧪 Falsifiable Predictions (1)

1 total 0 confirmed 0 falsified

Modulation of DGAT1 and SOAT1 will affect the proposed pathway

pending conf: 0.35

Expected outcome: DGAT1 and SOAT1 knockdown/overexpression shows measurable effect

Falsified by: No effect observed from DGAT1 and SOAT1 modulation in relevant models

Knowledge Subgraph (166 edges)

associated with (8)

P2RY1→neurodegenerationP2RX7→neurodegenerationBMAL1→neurodegenerationMIRO1→neurodegenerationP2RY1 and P2RX7→neurodegeneration

▸ Show 3 more

PIEZO1 and KCNK2→neurodegenerationDGAT1 and SOAT1→neurodegenerationHK2→neurodegeneration

co associated with (21)

BMAL1→DGAT1 and SOAT1BMAL1→MIRO1BMAL1→HK2BMAL1→TET2BMAL1→PIEZO1 and KCNK2

▸ Show 16 more

DGAT1 and SOAT1→MIRO1DGAT1 and SOAT1→HK2DGAT1 and SOAT1→TET2DGAT1 and SOAT1→PIEZO1 and KCNK2HK2→TET2HK2→PIEZO1 and KCNK2HK2→MIRO1MIRO1→TET2MIRO1→PIEZO1 and KCNK2BMAL1→P2RY1 and P2RX7DGAT1 and SOAT1→P2RY1 and P2RX7MIRO1→P2RY1 and P2RX7HK2→P2RY1 and P2RX7P2RY1 and P2RX7→TET2P2RY1 and P2RX7→PIEZO1 and KCNK2PIEZO1 and KCNK2→TET2

co discussed (118)

BMAL1→HK2BMAL1→MIRO1BMAL1→P2RY1BMAL1→SOAT1BMAL1→KCNK2

▸ Show 113 more

BMAL1→TET2BMAL1→PIEZO1BMAL1→P2RX7BMAL1→DGAT1BMAL1→C3HK2→MIRO1HK2→P2RY1HK2→SOAT1HK2→KCNK2HK2→TET2HK2→PIEZO1HK2→P2RX7HK2→DGAT1HK2→C3MIRO1→P2RY1MIRO1→SOAT1MIRO1→KCNK2MIRO1→TET2MIRO1→PIEZO1MIRO1→P2RX7MIRO1→DGAT1MIRO1→C3P2RY1→SOAT1P2RY1→KCNK2P2RY1→TET2P2RY1→PIEZO1P2RY1→P2RX7P2RY1→DGAT1P2RY1→C3SOAT1→KCNK2SOAT1→TET2SOAT1→PIEZO1SOAT1→P2RX7SOAT1→DGAT1SOAT1→C3KCNK2→TET2KCNK2→P2RX7KCNK2→DGAT1KCNK2→C3TET2→PIEZO1TET2→P2RX7TET2→DGAT1TET2→C3PIEZO1→P2RX7PIEZO1→DGAT1PIEZO1→C3P2RX7→DGAT1P2RX7→C3DGAT1→C3AQP4→BDNFAQP4→GDNFBDNF→GDNFC1Q→GDNFC1Q→TNFGDNF→TNFSOD1→TET2TAU→TET2C3→TET2C3→TIMP1TIMP1→TNFAPOE→RESTBDNF→C3C3→GDNFBDNF→TAUDGAT1→P2RY1DGAT1→P2RX7DGAT1→KCNK2DGAT1→PIEZO1P2RX7→HK2P2RX7→SOAT1P2RX7→BMAL1P2RX7→PIEZO1P2RX7→MIRO1P2RX7→KCNK2P2RX7→TET2C3→HK2C3→SOAT1C3→BMAL1C3→P2RY1C3→PIEZO1C3→MIRO1C3→KCNK2C3→DGAT1HK2→BMAL1SOAT1→BMAL1SOAT1→P2RY1SOAT1→MIRO1P2RY1→MIRO1PIEZO1→MIRO1PIEZO1→KCNK2PIEZO1→TET2DGAT1→TET2DGAT1→HK2DGAT1→BMAL1DGAT1→MIRO1P2RY1→HK2P2RY1→BMAL1SOAT1→HK2KCNK2→HK2KCNK2→BMAL1KCNK2→MIRO1PIEZO1→HK2PIEZO1→BMAL1TET2→HK2TET2→BMAL1TET2→MIRO1TET2→P2RY1TET2→SOAT1TET2→KCNK2MIRO1→BMAL1MIRO1→HK2C3→P2RX7C1Q→TET2

interacts with (6)

P2RY1→P2RX7P2RX7→P2RY1PIEZO1→KCNK2KCNK2→PIEZO1DGAT1→SOAT1

▸ Show 1 more

SOAT1→DGAT1

participates in (10)

P2RY1→Purinergic signalingP2RX7→Purinergic signalingTET2→Epigenetic regulationPIEZO1→Astrocyte reactivity signalingKCNK2→Astrocyte reactivity signaling

▸ Show 5 more

HK2→Insulin/IGF metabolic signalingBMAL1→Circadian clock / BMAL1-CLOCK transcriptionDGAT1→Astrocyte reactivity signalingSOAT1→Astrocyte reactivity signalingMIRO1→Mitochondrial dynamics / bioenergetics

targets (3)

h-0758b337→P2RY1 and P2RX7h-db6aa4b1→PIEZO1 and KCNK2h-7d4a24d3→DGAT1 and SOAT1

Mechanism Pathway for DGAT1 and SOAT1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_7d4a24d3["h-7d4a24d3"] -->|targets| DGAT1_and_SOAT1["DGAT1 and SOAT1"]
    DGAT1_and_SOAT1_1["DGAT1 and SOAT1"] -->|associated with| neurodegeneration["neurodegeneration"]
    BMAL1["BMAL1"] -->|co associated with| DGAT1_and_SOAT1_2["DGAT1 and SOAT1"]
    DGAT1_and_SOAT1_3["DGAT1 and SOAT1"] -->|co associated with| MIRO1["MIRO1"]
    DGAT1_and_SOAT1_4["DGAT1 and SOAT1"] -->|co associated with| HK2["HK2"]
    DGAT1_and_SOAT1_5["DGAT1 and SOAT1"] -->|co associated with| TET2["TET2"]
    DGAT1_and_SOAT1_6["DGAT1 and SOAT1"] -->|co associated with| PIEZO1_and_KCNK2["PIEZO1 and KCNK2"]
    DGAT1_and_SOAT1_7["DGAT1 and SOAT1"] -->|co associated with| P2RY1_and_P2RX7["P2RY1 and P2RX7"]
    style h_7d4a24d3 fill:#4fc3f7,stroke:#333,color:#000
    style DGAT1_and_SOAT1 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style BMAL1 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_2 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_3 fill:#ce93d8,stroke:#333,color:#000
    style MIRO1 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_4 fill:#ce93d8,stroke:#333,color:#000
    style HK2 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_5 fill:#ce93d8,stroke:#333,color:#000
    style TET2 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_6 fill:#ce93d8,stroke:#333,color:#000
    style PIEZO1_and_KCNK2 fill:#ce93d8,stroke:#333,color:#000
    style DGAT1_and_SOAT1_7 fill:#ce93d8,stroke:#333,color:#000
    style P2RY1_and_P2RX7 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 DGAT1 — PDB 6VP0 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Astrocyte reactivity subtypes in neurodegeneration

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Epigenetic Memory Erasure via TET2 Activation

Score: 0.74 · TET2

Metabolic Switch Targeting for A1→A2 Repolarization

Score: 0.73 · HK2

Circadian Rhythm Entrainment of Reactive Astrocytes

Score: 0.72 · BMAL1

Purinergic Signaling Polarization Control

Score: 0.71 · P2RY1 and P2RX7

Mechanosensitive Ion Channel Reprogramming

Score: 0.70 · PIEZO1 and KCNK2

→ View all analysis hypotheses

Lipid Droplet Dynamics as Phenotype Switches

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 9

✗ Opposing Evidence 6

Novel Therapeutic Hypotheses for Astrocyte Reactivity Subtypes in Neurodegeneration

Hypothesis 1: Metabolic Switch Targeting for A1→A2 Repolarization

Critical Evaluation of Astrocyte Reactivity Therapeutic Hypotheses

Hypothesis 1: Metabolic Switch Targeting for A1→A2 Repolarization

Specific Weaknesses:

Practical Feasibility Assessment: Astrocyte Reactivity Therapeutic Hypotheses

Most Viable Hypotheses for Drug Development

HYPOTHESIS 3: TET2 Activation (Revised Confidence: 0.50)

Druggability Assessment: MODERATE

Price History

Clinical Trials (5) Relevance: 44%

📚 Cited Papers (30)

📅 Citation Freshness Audit

📙 Related Wiki Pages (15)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

Wiki Pages

KG Entities (34)

Dependency Graph (1 upstream, 0 downstream)

Linked Experiments (5)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (1)

Knowledge Subgraph (166 edges)

associated with (8)

co associated with (21)

co discussed (118)

interacts with (6)

participates in (10)

targets (3)

Mechanism Pathway for DGAT1 and SOAT1

3D Protein Structure

Source Analysis

Astrocyte reactivity subtypes in neurodegeneration

Community Feedback

Same Analysis (5)